Yu-Chieh Wu

Yu-Chieh Wu

Auto-generated profile, based on publicly available information

Yu-Chieh Wu

School of Pharmacy College of Pharmacy China Medical University Taichung 40604 Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Current Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
CCChih-Shiang Chang
Chih-Shiang Chang
VKVathan Kumar
Vathan Kumar
DLDer-Yen Lee
Der-Yen Lee
YCYeh Chen
Yeh Chen
YWYu-Chieh Wu
Yu-Chieh Wu
PCPo-Chen Chu
Po-Chen Chu
Background: A growing body of evidence suggests that Hsp70, which is overexpressed in human breast tumors, plays a role in tumorigenesis and tumor progression in breast cancer as well as in its aggressive phenotypes. Hsp70 constitutes a potential therapeutic target in the treatment of this disease. Methods: We developed a new series of rhodacyanine-based Hsp70 inhibitors, represented by compounds 1 and 6, in which the cationic pyridin-1-ium or thiazol-3-ium ring of existing Hsp70 inhibitors (e.g., JG-40 and JG-98) was replaced by a corresponding benzo- fused N-heterocycle. Results: Several lines of evidence suggest that these benzo-fused derivatives may exert their antitumor activities, in part, by targeting Hsp70. These putative inhibitors displayed differential antiproliferative efficacy against breast cancer cells (IC50 as low as 0.25 μM) versus nontumorigenic MCF-10A breast epithelial cells (IC50 ≥ 5 μM). This was correlated with the corresponding Hsp70 expression levels. Using a protein refolding assay, we confirmed that these agents effectively inhibited the chaperone activity of Hsp70. Moreover, these inhibitors effectively suppressed the expression of well-known oncogenic client proteins of Hsp70’s, including FoxM1, HuR, and Akt, which paralleled their antiproliferative efficacy. Supporting the established role of Hsp70 in regulating protein refolding, these derivatives induced autophagy, as manifested by the conversion of LC3B-I to LC3B-II. Notably, these putative Hsp70 inhibitors did not cause a compensatory elevation in Hsp90 expression, contrasting with the previously reported effects of Hsp90 inhibitors on Hsp70 upregulation. Conclusion: Together with the finding that compounds 1 and 6 showed improved microsomal stability, these results suggest the translational potential of these putative Hsp70 inhibitors to foster new strategies for cancer therapy. However, whether these benzo-fused rhodacyanines act on kinases or other targets remains unclear. It is currently under investigation.

26 April 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
PCPo-Chen Chu
Po-Chen Chu
YWYu-Chieh Wu
Yu-Chieh Wu
CCChien-Yu Chen
Chien-Yu Chen
YHYu-Syuan Hung
Yu-Syuan Hung
CCChih-Shiang Chang
Chih-Shiang Chang
Aim: Tumor cells adapt to hypoxic microenvironments by releasing the key transcription factor HIF-1α, which promotes angiogenesis, glycolytic phenotype, metastasis and erythropoiesis, allowing prol...

20 September 2023 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
YWYu-Chieh Wu
Yu-Chieh Wu
MLMeng-Tien Lu
Meng-Tien Lu
PCPo-Chen Chu
Po-Chen Chu
CCChih-Shiang Chang
Chih-Shiang Chang
Background: The aminoquinoline core exhibits versatile pharmacological properties, particularly in the area of anticancer activity. This study was designed to investigate the potential of the 4-ami...